Company news
Protokinetix, Inc. (OTC:PKTX) news
Protokinetix, Inc. news releases on 6ix. Latest, Sep 3, 2026: ProtoKinetix Incorporated : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
Press releases & updates
ProtoKinetix Incorporated : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
September 3, 2026
ProtoKinetix Incorporated : Initial Statement of Beneficial Ownership (Form 3)
July 28, 2026
Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication
June 5, 2023
ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
July 20, 2022
ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only
January 14, 2022
ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease
November 23, 2021
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
May 12, 2021
ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes
April 22, 2021
ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®
April 14, 2021
Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration
April 7, 2021
Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision
November 24, 2020
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
September 15, 2020
Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada
August 27, 2020
ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing
August 14, 2020
Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada
July 13, 2020
ProtoKinetix AAGP® Dry Eye Program Advancing
July 7, 2020
ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease
April 6, 2020
ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials
March 24, 2020
ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease
March 19, 2020
ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine
February 19, 2020
ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine
February 11, 2020
ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial
January 24, 2020
ProtoKinetix AAGP® Dry Eye Therapy Testing Results
January 6, 2020
ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed
December 19, 2019
ProtoKinetix AAGP® Dry Eye Therapy Program Launched
November 22, 2019
ProtoKinetix AAGP® Operational Update
November 6, 2019
Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone
August 23, 2019
ProtoKinetix Reaches Mid-Point of 3rd Stage of Retinal Cell Replacement Therapy Testing at UBC
July 9, 2019
ProtoKinetix Achieves Primary Objective Safety at Midpoint of Clinical Trial
June 7, 2019
ProtoKinetix First in Series of Town Hall Shareholder Meetings
May 30, 2019
Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies
May 9, 2019
ProtoKinetix Discusses Investor Awareness Campaign and Recent Market Activity
May 6, 2019
ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program
April 23, 2019
ProtoKinetix Releases Third in a Series of Scientific Update Videos
February 26, 2019
ProtoKinetix Releases Second in a Series of Scientific Update Videos
January 16, 2019
ProtoKinetix Releases First in a Series of Scientific Update Videos
December 19, 2018
ProtoKinetix Begins Cardiovascular Research
September 28, 2018
ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions
September 4, 2018
ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBC
August 10, 2018
ProtoKinetix’s AAGP® Signs a Material Transfer Agreement with a Reputed International Biotech Company
June 13, 2018
ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery
January 10, 2018
The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to Immunotherapy
November 16, 2017
Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery
October 17, 2017
ProtoKinetix and Proactive Immune Sciences Announce a Joint Research Collaboration Using AAGP™ in Immune Cell Cryopreservation Testing
June 5, 2017
ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™
May 24, 2017
ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes
March 9, 2017
ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration
February 7, 2017
ProtoKinetix Announces Investigator Sponsored Human Clinical Trial Application Using AAGP™ Has Been Approved by Health Canada
January 24, 2017
ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP™ in the Treatment of Type 1 Diabetes
January 17, 2017
ProtoKinetix’ 2nd Quarter Scientific Update
July 14, 2016